Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

Abstract

Imaging of prostate cancer presents many challenges to the imaging community. There has been much progress in this space in large part due to MRI and PET radiopharmaceuticals. Though MRI has been focused on the evaluation of local disease and PET on the detection of metastatic disease, these two areas do converge and will be complementary especially with the growth of new PET/MRI technologies. In this review article, we review novel MRI, MRI/US, and PET radiopharmaceuticals which will offer insight into the future direction of imaging in prostate cancer.

• Authors: Phillip J Koo, Jennifer J Kwak, Sajal Pokharel, Peter L Choyke
• Journal: Current oncology reports (Curr Oncol Rep) Vol. 17 Issue 12 Pg. 56 (Dec 2015) ISSN: 1534-6269 [Electronic] United States
• PMID: 26462919 (Publication Type: Journal Article, Review)

Chemical References

• Radiopharmaceuticals

Topics

• Biopsy (methods)
• Humans
• Magnetic Resonance Imaging (methods)
• Male
• Multimodal Imaging (methods)
• Positron-Emission Tomography (methods)
• Prostatic Neoplasms (diagnosis, diagnostic imaging)
• Radiopharmaceuticals (administration & dosage)
• Tomography, X-Ray Computed
• Ultrasonography